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Abstract
Background: Clinical efficacy of chemotherapy in colorectal cancer is subjected to broad inter-individual variations
leading to the inability to predict outcome and toxicity. The topoisomerase I inhibitor irinotecan (CPT-11) is
worldwide approved for the treatment of metastatic colorectal cancer and undergoes extensive peripheral and
tumoral metabolism. PXR is a xenoreceptor activated by many drugs and environmental compounds regulating
the expression of drug metabolism and transport genes in detoxification organs such as liver and gastrointestinal
tract. Considering the metabolic pathway of irinotecan and the tissue distribution of Pregnane × Receptor (PXR),
we hypothesized that PXR could play a key role in colon cancer cell response to irinotecan.
Results: PXR mRNA expression was quantified by RT-quantitative PCR in a panel of 14 colon tumor samples and
their matched normal tissues. PXR expression was modulated in human colorectal cancer cells LS174T, SW480 and
SW620 by transfection and siRNA strategies. Cellular response to irinotecan and its active metabolic SN38 was
assessed by cell viability assays, HPLC metabolic profiles and mRNA quantification of PXR target genes. We showed
that PXR was strongly expressed in colon tumor samples and displayed a great variability of expression. Expression
of hPXR in human colorectal cancer cells led to a marked chemoresistance to the active metabolite SN38
correlated with PXR expression level. Metabolic profiles of SN38 showed a strong enhancement of SN38
glucuronidation to the inactive SN38G metabolite in PXR-expressing cells, correlated with an increase of
UDPglucuronosyl transferases UGT1A1, UGT1A9 and UGT1A10 mRNAs. Inhibition of PXR expression by lentivirus-
mediated shRNA, led to SN38 chemoresistance reversion concomitantly to a decrease of UGT1A1 expression and
SN38 glucuronidation. Similarly, PXR mRNA expression levels correlated to UGT1A subfamily expression in human
colon tumor biopsies.
Conclusion: Our results demonstrate that tumoral metabolism of SN38 is affected by PXR and point to potential
therapeutic significance of PXR quantification in the prediction of irinotecan response. Furthermore, our
observations are pharmacologically relevant since many patients suffering from cancer diseases are often exposed
to co-medications, food additives or herbal supplements able to activate PXR. A substantial part of the variability
observed among patients might be caused by such interactions
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Colorectal cancer is the fourth most common cancer in
men and the third in women worldwide, and is cur-
rently undergoing a rapid increase in incidence [1].
Approximately two-thirds of patients present potentially
curable disease but 30-40% will relapse with metastatic
disease. Despite the emergence of targeted therapies,
chemotherapy based on conventional fluoropyrimidine
associated either with the platinum salt oxaliplatin or
with the topoisomerase inhibitor irinotecan remains the
first-line treatment [2]. Yet, clinical efficacy of these
drugs is limited by the inability to predict chemotherapy
outcome and toxicity. Notably, broad inter-individual
v a r i a t i o n si nt e r m so fr e s p o n s ea sw e l la so ft h eo c c u r -
rence of severe toxic side-effects like diarrhea and neu-
tropenia are detected following treatment with
compounds such as irinotecan [3]. In this context, iden-
tification of biological markers allowing the prediction
of both therapeutic and toxic response is a priority
issue.
Irinotecan (or CPT-11) is a water-soluble derivative of
camptothecin acting as a topoisomerase I inhibitor and
currently registered for use in patients with metastatic
colorectal cancer. Irinotecan itself has weak, if any,
pharmacological activity in vitro. It is thought to exert
its antitumor activity in vivo after enzymatic cleavage by
carboxylesterases 1 and 2 (predominantly in the liver
but also partly at the tumor site) that generate the active
metabolite SN38. Irinotecan and SN38 are then sub-
jected to extensive intracellular catabolism yielding inac-
tive metabolites. Irinotecan undergoes phase I oxidation
by cytochromes P450 3A4 and 3A5 leading to oxidized
inactive metabolites whereas SN38 is metabolised to
SN38G through phase II glucuronidation by the UDP-
glucuronosyl transferases 1A1, 1A6, 1A9 and 1A10 [4,5].
In addition, irinotecan and its metabolites are subjected
to extracellular efflux through transporters, including P-
glycoprotein (MDR1), multidrug resistance-related pro-
tein-2 (MRP2) and breast cancer resistance protein
(BCRP) [6,7]. Numerous studies have focused on periph-
eral irinotecan metabolism, and genetic polymorphisms
within genes coding for enzyme implicated in the irino-
tecan metabolic pathway have been extensively
described. Notably, detection of the UGT1A1*28 geno-
type, found to be predictive for SN38 peripheral glucur-
onidation and irinotecan toxicity [8], is now
r e c o m m e n d e db yt h eU SF o o da n dD r u gA d m i n i s t r a -
tion. However, conflicting results on UGT1A1*28 and
the plethora of studies on others sequence variations in
UGT1A1,b u ta l s oi nABCB1, ABCC1 or HNF1A genes,
suggests that reliable predictions of SN38 exposures
cannot be based on the detection of a single polymorph-
ism [9]. Inter-individual variation may be due to a
combination of many genetic and non-genetic factors
(diet, co-medications, etc.). Indeed, irinotecan pharmaco-
kinetics and disposition is affected by various com-
pounds now identified as ligands of the xenosensor PXR
(Pregnane × Receptor, NR1I2) such as rifampicin [10] or
St. John’s wort [11].
PXR is a nuclear receptor acting as a “molecular senti-
nel” able to bind to a large variety of structurally diverse
compounds included drugs, food additive or environ-
mental toxics [12]. It coordinates the detoxification of
many lipophilic xenobiotics via transcriptional regula-
tion of a large number of metabolizing enzymes and
transporters [13]. Targets genes of PXR are CYP3A4
[14], MDR1 [15], CYP2B6 [16], members of UGTs
superfamily [17] and transporters like the multidrug
resistance-related protein-3 (MRP3) [18] or the organic
anion transporting polypeptide-2 (OATP2) [19]. PXR is
predominantly expressed in liver and in intestinal tract,
but little is known about its expression in tumors.
B e c a u s eP X Rc o n t r o l st h ee x p r e s s i o no fk e yg e n e s
involved in anticancer drugs disposition, recent works
have focused on its potential role in drug resistance
[20]. For instance, PXR is suspected to play a role in
both all-trans retinoic acid [21] and etoposide [22] resis-
tances through an enhancement of their CYP3A4-
mediated metabolism. In addition, it has been shown
that PXR induces cell proliferation and inhibits apopto-
sis in human colon cancer cells [23]. Considering the
metabolic profile of irinotecan and the tissue distribu-
tion of PXR, we aimed to assess to what extent PXR
could affect metabolism and colon cancer cell response
to irinotecan. We show that expression of PXR in
human colorectal cancer cells led to irinotecan and
SN38 chemoresistance through enhancement of its
glucuronidation.
Materials and methods
Cell lines, plasmids and transfections
The human colorectal cancer cells LS174T were kindly
provided by Dr. Pierre Martineau (IRCM, Montpellier,
France). SW480, SW620, HCT116, HT29, HepG2 and
HuH7 were from the cells collection of the Macromole-
cular Biochemistry Research Center (Montpellier,
France). All cell lines were grown in RPMI 1640 supple-
mented with 10% fetal calf serum (FCS), 2 mmol/l gluta-
mine, 100 units/ml penicillin and streptomycin.
Selection mediums for transfected cells were supple-
mented with 250 μg/ml (SW480 and SW620) or 500 μg/
ml (LS174T) geneticin. Cells were maintained routinely
at 37°C in 5% CO2 humidified atmosphere.
PXR expression vector was built by cloning hPXR-1
cDNA (NM_003889) [14] in a pcDNA3 vector (Invitro-
gen). Stable clones overexpressing PXR were obtained
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using lipofectamine LTX transfection reagent (Invitro-
gen), according to manufacturer’s instructions. Parent
LS174T cells were transfected with empty pcDNA3 vec-
tor to yield control mock-transfectant. The shRNA-
expressing vectors were constructed by cloning shRNA
expression cassettes into FG12 lentiviral vector [24]
(additional file 1). Cells were transduced with lentiviral
vectors and GFP positive cells were isolated using a BD
FACSAria™ cell sorter as previously reported [25].
Human specimen samples
Specimens of liver and colon biopsies were obtained
from the pathologist after resection according to French
government regulations and with approval of the ethical
committee (Montpellier and Nîmes Hospitals). Informed
consent was obtained from all patients. Tissue samples
were stored in liquid nitrogen until further use.
Chemicals
Irinotecan, 5-fluorouracil (5-FU), oxaliplatin and verapa-
mil chlorhydrate solutions were provided by the depart-
ment of Pharmacy of the Nimes university hospital.
SN38 was a kind gift from Dr E. Chatelut (Claudius
Regaud Institute, Toulouse, France). Dimethysulfoxide
(DMSO), rifampicin, ketoconazole, fumitremorgin C and
L-Sulforaphane (SFN) were purchased from Sigma-
Aldrich.
RNA extraction and reverse transcription
Total RNA were extracted using RNAeasy kit (Qiagen),
according to the manufacturer’s instructions. RNA
quantity and quality of samples were determined by the
260:280 nm absorbance ratios using a NanoDrop spec-
trophotometer (Thermo Fisher Scientific). One μgo f
total RNA from each sample was added to 8.4 μlo f
reverse transcription mix containing 4 μlo ff i r s ts t r a n d
buffer 5×, 0.4 μlo fd N T Pm i x2 5m M ,2μlo fd i t h i o -
threitol 10×, 1 μlo fo l i g o d Tp r i m e rs o l u t i o na n do f
MLV-RT enzyme 200 U/μl. Solution volumes were
adjusted to 20 μl by adding RNase free water. Samples
were placed at 37°C for 1 hour and at 65°C for 5 min-
utes. cDNA solution volumes were adjusted to 100 μlb y
adding 80 μl of PCR grade water and stored at -20°C for
further analysis.
Real-time quantitative PCR
m R N A se x p r e s s i o nw a se v a l u ated by RT-quantitative
PCR, using a LightCycler 480 real-time PCR system and
SYBRGreen PCR master mix 2× (Roche Diagnostics) in
96-well plates. Quantitative PCR was done using gene-
specific primers and b-actin was used as reference gene
(additional file 2). Standard curves were generated for
all genes by serial dilution of cDNAs. After
normalization of threshold cycle values with the amount
of b-actin, gene expression levels were expressed as
ratios compared with that of vehicle-treated cells. Each
sample was run three times in duplicates, and data were
analyzed using the 1.5 version of LightCycler 480 soft-
ware (Roche Diagnostics). Standard curves were gener-
ated for all genes by serial dilution of cDNAs from
LS174T control for relative quantification in cultured
cells and from a pool of human liver biopsies for relative
quantification in tumors.
Western Immunoblotting
Protein extracts were prepared from cells by using M-
PER® mammalian protein extraction reagent (Thermo
Scientific) in presence of a protease inhibitor cocktail
(Roche), according to the manufacturer’sp r o t o c o l .P r o -
teins (40 μg/lane) were separated by 12% SDS-polyacry-
lamide gel electrophoresis and transferred to a
PROTRAN® nitrocellulose membrane (Schleicher and
Schuell). Membranes were sequentially incubated with
anti-hPXR (G-11, Santa Cruz Biotechnology) or anti-
bactin (Santa Cruz Biotechnology) primary antibody,
and with peroxidase-conjugated anti-mouse IgG (Santa
Cruz Biotechnology). Signals were detected by chemolu-
minescence using ECL Western Blotting Detection
reagents (GE Healthcare).
Immunohistochemistry
Tissues were embedded in paraffin and sections (5 μm)
were dewaxed in a xylene bath and rehydrated in graded
alcohols. Endogenous peroxidase activity was quenched
with 1.5% H2O2 in methanol for 20 min. and washed in
PBS. Antigen retrieval was performed by boiling slides
in 10 mM sodium citrate buffer, pH 6.0. Nonspecific
binding sites were blocked with 1% BSA, 3% normal
goat serum, and 0.2% Triton X-100 in PBS for 1 h at
RT. Slides were incubated with the primary anti-human
polyclonal PXR antibody (Lifespan Biosiences) overnight
at 4°C in 50 times-diluted blocking buffer. Universal
immuno-peroxydase polymer anti-mouse Histofine®
(Nichirei Biosciences, Japan) was used as a secondary
reagent, stainings were developed with DAB (brown pre-
cipitate, SIGMA) and hematoxylin counterstain was
used. After dehydration, sections were mounted in Per-
tex (Histolab). Then, slides were scanned with high
resolution Nanozoomer (Hamamatsu).
Neutral red chemotherapeutic sensitivity assays
Experimental conditions for neutral red assays were
adapted from a previously described protocol [26].
Briefly, 20.000 cells were seeded in 96-well microtiter
plates. After 24 h incubation, cells were treated for 72 h
with increasing concentrations of cytotoxics. After a
neutral red incubation at 37°C for four hours, cells were
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cial acetic acid/50% ethanol (vol:vol). The absorbance at
540 nm was measured using a microplate reader (iEMS,
Labsystems). The effect of the drugs on cell survival was
expressed as the percentage of cell viability compared to
untreated cells.
Irinotecan metabolites detection assay
Cells were seeded in six-well plates at 10
6 cells/well,
incubated for 24 hours, and then treated with 0.1%
DMSO (solvent) or 10 μM SN38 for 24 h. Cell pellets
and supernatants were stored at -80°C for further analy-
sis. Cell pellets were dissolved in 500 μl of a mixture of
methanol-acetonitrile (50:50 vol:vol). 400 μlo fc u l t u r e
supernatants were added to 800 μl of the mixture of
methanol-acetonitrile (50:50 vol:vol). After proteins
denaturation by full-speed vortex mixing, samples were
then centrifuged at 13000 rpm for 3 minutes. 550 μlo f
clear supernatants were mixed to 250 μlo f1MH C l
and used for HPLC injection. Irinotecan and its metabo-
lites were detected and quantified by a HPLC method as
previously described [27].
Statistical analysis
The Mann and Whitney test was used to analyze the
difference between two groups of quantitative variables.
Alpha value was set at 5%. For comparisons among
three groups of quantitative variables, the Kruskal Wallis
test was used. In cases where there was a significant dif-
ference between the groups, a pairwise comparison was
carried out by adjusting the alpha risk by the method of
Bonferroni. Student’s t-tests were performed when indi-
cated in figures legends. All statistical analyses were car-
ried out by the Department of biostatistics,
epidemiology, public Health and medical information of
the Nîmes University Hospital using the SAS software
(SAS Institute Inc.).
Results
Expression of hPXR in colon tissues and colon cancer
cells
To examine whether hPXR is expressed in human colon
in vivo, we analyzed its mRNA expression in both nor-
mal and neoplastic human colon tissues. Human liver
tissues, which are known to have high-PXR expression,
were used as positives controls. As shown in figure 1A,
PXR mRNA was detected in both normal and cancerous
human colon tissues. In our panel of 14 patients, PXR
mRNA was more abundant in some colon tissues than
in liver biopsies, and displayed a greater variability in
colon tissues than in liver tissues. Note that, although
we did observe some quantitative differences between
the expression of PXR in normal tissues and their
matched colon tumour samples, we found no clear
trend of tendency (figure 1B). In addition, we observed
a very low expression of PXR mRNA in both colon can-
cer cells lines LS174T, SW480, SW620, or HT29 and
hepatic cell lines HepG2 and HuH7 (figure 1C). This
result on cell lines is in accordance with the previous
observation that cultured cells often loose metabolic
abilities and PXR expression [28]. Representative exam-
ples of PXR immunostaining are displayed in figure 1D,
liver were used as positive control for PXR expression
and negative controls without primary antibody are
shown (photos a, c and d). We observed a strong immu-
nostaining of PXR in both normal colon and tumors
consistent with mRNA results.
Functional characterization of PXR transfected LS174T
colorectal cancer cells
To decipher the role of PXR in irinotecan-mediated
toxicity in colorectal cancer cells, we first established
stable clones overexpressing hPXR in LS174T. These
cells were chosen because of their low, but detectable,
PXR mRNA expression, and their well known sensitive-
ness toward both irinotecan and SN38 [29]. In addition
these cells express a functional p53 [30], which is partly
involved in irinotecan response [31]. As shown in figure
2A, we selected three clones harbouring different PXR
expression levels at both mRNA and protein levels
(PXR2 ≈ PXR6 >> PXR3). Basal expression levels of
CYP3A4 mRNA were higher (up to 9.31 ± 2.40 fold for
PXR6) in PXR-expressing cells compared to controls
(figure 2B) and were further increased by rifampicin
(48.92 ± 1.07 fold for PXR2, 19.02 ± 6.83 fold for PXR3
and 92.25 ± 3.60 fold for PXR6 compared to controls).
In agreement with the very low level of endogenous
PXR detected in these cells, we observed a very weak
increase of CYP3A4 mRNA levels upon treatment of
parent and pcDNA3-transfected cells with rifampicin.
The growth rate of PXR-transfected cells did not signifi-
cantly vary from that of pcDNA3-transfected cells (fig-
ure 2C)
PXR induces colorectal cancer cells resistance to
irinotecan and SN38
To evaluate the role of PXR onto cell sensitivity to
d r u g su s e di nt h et r e a t m e n to fa d v a n c e dc o l o r e c t a l
cancer we first carried out neutral red cell viability
assays. For this purpose, control and PXR-transfected
LS174T clones were maintained for 72 hours in the
presence of increasing concentrations of irinotecan,
SN38, 5-fluorouracil or oxaliplatin. As shown in figure
3, PXR expression clearly led to an increased survival
of LS174T cells towards irinotecan and SN38, and the
level of chemoresistance to SN38 was correlated to
the relative PXR expression level of each clone (figure
3B). Upon treatment with 1 μMS N 3 8 ,P X R -
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(36.56% ± 4.05 surviving cells for PXR2 and 26.05% ±
1.82 for PXR6) compared to pcDNA3-transfected cells
(3.93% ± 1.64). We found no difference in topoisome-
rase I activity between pcDNA3-transfected cells and
PXR-transfected cells demonstrating that the observed
chemoresistance is not due to a variation of topoi-
somerase I expression after PXR transfection (addi-
tional file 3)
As expected, cells were more sensitive to SN38 than to
irinotecan, the latter undergoing minimal conversion
into its active metabolite due to very low expression
level of carboxylesterases in these cells (additional file
4). In addition, cell viability assays performed in SW480
and SW620 cell lines stably transfected with hPXR,
showed similar PXR-dependent enhancement of SN38
resistance (additional file 5). On the other hand, we
found no effect of PXR expression on cell sensitivity to
Figure 1 Evaluation of PXR expression in human colorectal tissues and cell lines. A, PXR mRNA expression measured by quantitative real-
time PCR in human livers (n = 17) and colon samples (tumoral and healthy adjacent tissue, n = 14). Bars on graph represent mean PXR mRNA
expression and SEM. B, Percentage of PXR expression in colon tumors compared to adjacent healthy tissue; bars, SEM. C, PXR mRNA expression
in various colon (LS174T, HT29, HCT116, SW480, SW620) and hepatic (HepG2, HuH7) cell lines compared to livers (FT305 and 310) and to normal
(N61) and tumoral (T61) colon tissues. D, Immunocytochemical staining for PXR on liver, normal colon and tumors tissues. Liver was used as
positive control for PXR expression (b), photos a, c and d display negative controls without primary antibody.
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tional file 6).
Surprisingly, we observed that rifampicin did not
enhance the resistance of cells to SN38 (figure 4A).
These observations suggest that activation of PXR is not
required for these effects or that PXR is already acti-
vated under these conditions. While neither SN38 nor
irinotecan activate PXR (additional file 7), we found
that PXR was activated in our assays because of the pre-
sence of 10% fetal calf serum, as previously observed in
the HepG2 cell line [32]. Accordingly, in presence of
serum, CYP3A4 is highly expressed in PXR2 cells, with
no additional effect of rifampicin, in contrast to what
we observed in absence of serum (figure 4B). Moreover,
we found that the pharmacological PXR inhibitor L-sul-
foraphane (SFN) [33] decreased the percentage of cell
survival in PXR2 cells treated with 1 or 5 μMS N 3 8
(15.13% ± 3.99 and 1.72% ± 0.65), compared to cells
treated with SN38 alone (31.44% ± 3.31 and 9.32% ±
1.14) (figure 4C). Although we cannot completely
exclude off-target effects of SFN, it is likely that inhibi-
tion of PXR by SFN contributes toward decreased PXR2
cell resistance.
Inhibition of PXR expression reverses chemoresistance to
SN38
Because SFN is known to affect several other signaling
pathways, such as those involving the transcription fac-
tors Nrf2 [34] and NF-kappaB [35] that are known to
affect cell sensitivity to cytotoxics, we then used a more
specific strategy to inhibit PXR expression. For this pur-
pose, LS174T-CTRL or PXR2 cells were transduced
with control or shRNA-expressing lentiviral vectors as
described in the material and methods section. Although
PXR expression was partially decreased in PXR2 cells
transduced with control FG12 virus (PXR2-mock) com-
pared to the untransduced PXR2 clone (figure 5A), a
stronger decrease was detected in PXR2 cells transduced
with shRNA constructs selectively directed against the
PXR mRNA. Thus, we observed that PXR2 cells trans-
duced with the sh1334 construct presented a strong
decrease of both PXR mRNA and protein levels, while
PXR2 transduced with sh2116 displayed a moderate, if
any, decrease of PXR expression. Accordingly, induction
of CYP3A4 mRNA expression after rifampicin treatment
in serum-free medium was observed in PXR2-mock and,
to a lesser degree, in PXR2-sh2116 cells, but was lost in
PXR2-sh1334 cells (figure 5B). In addition, we carried
out neutral red viability assays on these clones (figure
5C), and detected a strong reversion of chemoresistance
to SN38 in PXR2-sh1334 cells at 0.1 μM (6.56% ± 1.75
compared to 38.78 ± 5.74 in PXR2-mock), demonstrat-
ing that the inhibition of PXR expression by itself is suf-
ficient to enhance chemosensitivity to SN38.
Figure 2 Characterization of LS174T PXR-transfected cells. A,
PXR expression level in parent LS174T, pcDNA3-transfected and
stable clones PXR2, PXR3 and PXR6 (top: mRNA expression level;
bottom: protein expression level). * p < 0.05, PXR expression of
stable clones compared to parent and pcDNA3-transfected cells,
assayed by Mann and Whitney test. B, CYP3A4 mRNA expression
levels of CTRL and PXR overexpressing clones treated 24 h by
solvent (0.1% DMSO) or 10 μM rifampicin in serum-free medium.
Results were obtained from three separate experiments; bars, SEM.
a, CYP3A4 expression of cells treated by rifampicin compared to the
vehicle treated groups, b, CYP3A4 expression of vehicle treated
stable clones compared to vehicle treated; assayed by Mann and
Whitney test (p < 0.05). C, proliferation rate of cell lines. Cells were
seeded in six-well plates at 5 × 10
5cells/well and counted at the
indicated times after seeding (Z1 counter, Beckman Coulter). Data
from three separate experiments; bars, SEM.
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Page 6 of 13Figure 3 Increased chemoresistance in PXR overexpressing cells to irinotecan and SN38. For neutral red assays, cells were treated for 72 h
by increasing concentrations of irinotecan (A) or SN38 (B). Columns, mean viability as a percentage of control (i.e., cells without
chemotherapeutics treatment, 100%) from replicates (n = 6) from six separate experiments; bars, SEM. a, viability percentages of PXR2, PXR3 and
PXR6 compared to pcDNA3-transfected cells (p < 0.05) (Mann and Whitney test). b, viability percentages of PXR2, PXR3 and PXR6 compared to
each other using Kruskal Wallis test (p < 0.05).
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PXR2 cells treated with rifampicin (RIF). Cells were cultured 24 h
with DMSO 0.1% (solvent) or 10 μM rifampicin in 10% serum
containing medium and then exposed to SN38 for 72 h. Columns,
mean viability as a percentage of control (i.e., cells without
chemotherapeutics treatment, 100%) from replicates (n = 6) from
three separate experiments; bars, SEM. B, CYP3A4 mRNA expression
level of pcDNA3-transfected or PXR-expressing cells cultured with
(10%) or without serum and treated with solvent (0.1% DMSO) or
10 μM rifampicin for 24 h. Results were obtained from three
separate experiments; bars, SEM. * p < 0.05 (Mann and Whitney
test), CYP3A4 mRNA expression of cells cultured with serum, with or
without rifampicin compared to vehicle treated cells. C, cell viability
assay on pcDNA3-transfected and PXR2 cells treated with PXR
antagonist L-Sulforaphane (SFN). Cells were cultured in presence of
solvent (DMSO 0.1%) or 10 μM L-Sulforaphane in serum containing
medium for 24 h followed by the 72 h treatment of SN38 with or
without SFN co-treatment. Columns, mean viability as a percentage
of control (i.e., cells without chemotherapeutics treatment, 100%)
from replicates (n = 6) from three separate experiments; bars, SEM.
*** p < 0.001, * p < 0.05 (student’s t-test).
Figure 5 Reversion of chemoresistance in PXR2 by PXR shRNA.
A, quantification of PXR expression by quantitative PCR (top) and
western blot (bottom). * p < 0.05 (Mann and Whitney test), PXR
expression in PXR2-Mock, PXR2-sh1334 and PXR2-sh2116 cells
compared to pcDNA3-Mock cells. B, quantification of CYP3A4 mRNA
expression after treatment by solvent (DMSO 0.1%) or 10 μM
rifampicin for 24 h in serum-free medium. * p < 0.05 (Mann and
Whitney test), CYP3A4 expression of cells treated by rifampicin
compared to the vehicle treated groups. C, cell viability assay on
pcDNA3-Mock, PXR2-Mock, PXR2-sh1334 and PXR2-sh2116 toward
SN38. Columns, mean viability as a percentage of control (i.e., cells
without chemotherapeutics treatment, 100%) from replicates (n = 6)
from six separate experiments; bars, SEM. Student’s t-test where
performed between CTRL-mock cells to PXR2-Mock, PXR2-sh1334
and PXR2-sh2116: *** p < 0.001, ** p < 0.01, * p < 0.05.
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Since PXR expression does not affect colon cancer cells
proliferation, we hypothesized that SN38 resistance
observed in PXR-expressing cells is likely mediated
through transcriptional regulation of genes involved in
drug metabolism. We first explored several steps of iri-
notecan metabolism by using pharmacological inhibitors
of CYP3A4 (ketoconazole), MDR1 (verapamil) and
BCRP (fumitremorgin C). None of these compounds
was able to reverse the PXR-dependent chemoresistance
(data not shown). We next assessed the metabolic pro-
file of SN38 using a previously described chromato-
graphic detection [27]. Raw data of peak area for
intracellular and extracellular SN38 and SN38G allowed
us to calculate the metabolic ratios SN38G/SN38.
Figure 6A displays relative proportions of total
amounts (intra- and extracellular) of SN38 and SN38G.
We found a very significant enhancement of SN38 glu-
curonidation in PXR-transfected cells. As shown in fig-
ure 6B, both intracellular and extracellular SN38G/SN38
ratios were significantly increased in cells overexpressing
PXR concordant with PXR expression level of clones.
Accordingly, PXR inhibition in PXR2-sh1334 cells
resulted in a decrease of SN38G levels compared to
those found in PXR2-mock or PXR2-sh2116 cells (figure
6C). Because the SN38G/SN38 ratio is a sensitive func-
tional marker of UGT1A1, 6, 9 and 10 enzymes, we
measured their relative expression by quantitative RT-
PCR. UGT1A1 mRNA expression was found to increase
proportionally to the PXR expression levels in PXR-
transfected cells (figure 7A). In addition, we also
observed a lower, but significant overexpression of both
UGT1A9 and UGT1A10 mRNA in those cells, while
UGT1A6 mRNA was unaffected. In the same way, we
observed a decrease of UGT1A1 mRNA expression in
siRNA transfected cells (figure 7B). Taken together,
these data strongly suggest that PXR significantly lowers
SN38 concentration by increasing SN38 metabolism to
its glucuronide conjugate, mainly through induction of
UGT1A1.
Discussion
In this work, we address whether expression of PXR in
human colorectal cancer cells could interfere with their
sensitivity and metabolism of drugs used in treatment of
advanced colorectal cancer. First we showed that hPXR
is expressed in both normal and neoplastic human
colon tissues with a strong variability in cancer colon
tissues. This variability may prove clinically relevant,
since a major finding of this study is that expression of
PXR in human colorectal cancer cells leads to chemore-
sistance to the active metabolite of irinotecan, SN38,
whereas it did not affect their sensitivity to both 5-fluor-
ouracil and oxaliplatin sensitivities. The opposite effect
obtained with pharmacological inactivation of PXR or
shRNA-mediated PXR down regulation confirmed the
direct involvement of PXR in SN38 chemoresistance.
However, in contrast to previous studies showing that
PXR affects intrinsic cell survival through the p53 sig-
naling pathway [23] and cell growth [36], we found that
PXR induced SN38 chemoresistance in LS174T (p53
wt)
as well as in SW480 and SW620 (p53
mut) without affect-
ing their intrinsic proliferation rates. Instead, we
observed that PXR expression lowered cellular SN38
concentration while increasing SN38 metabolism to its
glucuronide conjugate. Accordingly, we found that sev-
eral UGT1A isoenzymes were up-regulated in PXR-
expressing cells, most notably UGT1A1 which is the key
enzyme responsible of the inactivation of SN38 to
SN38G.
Since PXR activation (or inhibition) appears to
increase (or decrease) SN38 conversion to SN38G, our
results highlight the central role of PXR in regulating
the cytotoxic threshold of cells to irinotecan-based che-
motherapy. Several studies have demonstrated that iri-
notecan pharmacokinetics and disposition are affected
by various compounds now identified as PXR ligands
such rifampicin [10], phenobarbital [37], valproic acid
and other anticonvulsivant therapies [38,39] or natural
products including St. John’sw o r t( Hypericum perfora-
tum) [11]. In addition, our data are in accordance with
previous studies reporting that intratumoral expression
level of UGT1A isoforms may represent a mechanism of
intrinsic irinotecan resistance in colon cancer [40,41].
Interestingly a significant (r
2 = 0.72, p < 0.001) correla-
tion between PXR and UGT1A1 mRNA levels was
found in human colon tumors (figure 8). Taken
together, these data suggest that tumoral metabolism is
potentially affected by environmental or diet stimuli and
this should be taken into account in the prediction of
irinotecan disposition in patients. In addition, it is
known that diarrhea, a major limiting toxicity of irinote-
can, is due to SN38 accumulation in enterocytes [42]
and it is conceivable that in situ glucuronidation by
tumors and adjacent tissues depends on PXR expression
levels.
Considering its role as master xenobiotics responsive
receptor linking DME genes expression to environment
stimuli, we think that differences in PXR expression
contribute to the well known intra- and inter-subject
variability in irinotecan response, and that they partici-
pate in the difficulty to clearly identify factors responsi-
ble for pharmacogenetics of irinotecan, the so-called
“irinogenetics” [43-45]. Indeed, environmental com-
pounds, nutrition and diet affecting PXR expression
and/or activation may mask or attenuate pharmacoge-
netic associations. Moreover, PXR itself display strong
genetic polymorphism with more than 300 reported
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Page 9 of 13Figure 6 HPLC quantification of SN38 and SN38G A, Relative percentage of total amounts (intra- and extracellular) of SN38 and
SN38G on pcDNA3, PXR2, PXR3 and PXR6 cells after 24 h incubation with 10 μM SN38. Results were obtained from three separate
experiments; bars, SEM. B, Intracellular and extracellular SN38G/SN38 ratios on pcDNA3, PXR2, PXR3 and PXR6 cells after 24 h incubation with 10
μM SN38. Results were obtained from three separate experiments; bars, SEM. *** p < 0.001, ** p < 0.01, * p < 0.05 (student’s t-test) compared to
CTRL cells. C, representative chromatograms of extracellular medium of pcDNA3-Mock, PXR2-Mock, PXR2-sh1334 and PXR2-sh2116 cells exposed
to SN38.
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Page 10 of 13SNPs in the dbSNPs database, some of which well char-
acterized and inducing differences in both gene expres-
sion and ligand recognition [43,44]. PXR expression
levels within tumors could be also affected by non-
genetic factors such as intra-tumor inflammatory cyto-
kines [46], microRNA 148a [47] and methylation status
of its exon 3 [48]. In this context, discriminating the
roles of genetic influences from environmental effects in
drug response, recently coined “pharmacoecology” [49],
will be even harder as expected. Thus, it will be of inter-
est to evaluate the relative importance of these genetic
and non-genetic factors in patient response toward iri-
notecan-based chemotherapy.
Conclusion
In view of the present findings, clinical studies are now
needed to evaluate the potential interest of PXR in per-
sonalized medicine. Indeed, PXR expression and/or acti-
vation level could help physicians in the choice of
appropriate chemotherapy regimen for colorectal cancer
patients, since therapeutic alternatives to irinotecan
already exist (i.e. platinum salt or targeted therapy).
Finally, PXR down-regulation could be considered as a
novel therapeutic approach to circumvent chemoresis-
tance to chemotherapy.
Additional file 1: Sequences of shRNA cassettes used for the
inhibition of PXR expression. The shRNA-expressing vectors were
constructed by cloning shRNA expression cassettes into FG12 lentiviral
vector.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-46-
S1.PDF]
Additional file 2: Primers sequences used for the quantification of
PXR and its target genes by qPCR. mRNAs expression was evaluated
by RT-quantitative PCR using a LightCycler 480 real-time PCR system and
gene-specific primers, b-actin was used as reference gene.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-46-
S2.PDF]
Figure 7 A, UGT1As mRNA expression levels in pcDNA3, PXR2, PXR3 and PXR6 cells. Results were obtained from six separate experiments;
bars, SEM. ** p < 0.01, * p < 0.05 (student’s t-test) compared to CTRL cells. B, UGT1A1 mRNA expression levels in CTRL-Mock, PXR2-Mock, PXR2-
sh1334 and PXR2-sh2116 cells. Results were obtained from four separate experiments; bars, SEM. *** p < 0.001, * p < 0.05 (student’s t-test)
compared to CTRL-Mock cells.
Figure 8 Correlation of PXR and total UGTs mRNA expression
in colon tumors (n = 14). Correlation coefficient R
2 = 0.72, *** p <
0.001. Doted lines: SEM for a 95% CI.
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Page 11 of 13Additional file 3: Topoisomerase I activity in LS174T pcDNA3 and
PXR-transfected cells. Topoisomerase I activity was assessed by using a
kit from TopoGen based on the ability of nuclear extracts to yield relaxed
plasmid from supercoiled plasmid substrate DNA. Nuclear extracts from
LS174T pcDNA3 and PXR-transfected cells were incubated for 15, 30 and
60 minutes with a supercoiled DNA marker subsequently subjected to
agarose electrophoresis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-46-
S3.PDF]
Additional file 4: Carboxylesterases mRNA quantification.
Carboxylesterases (CES1 and CES2) expression level in LS174T pcDNA3
transfected-cells, stable clone PXR2 and a pool of cDNA extracted from
liver biopsies. Results were obtained from six separate experiments; bars,
SEM.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-46-
S4.PDF]
Additional file 5: Characterization of SW480 and SW620 PXR-
transfected cells. A, C, PXR expression level in control and stable clones
SW480-PXR1, SW620-1L and SW620-1H (U, undetectable PXR expression
level). LS174T CTRL cells were taken as a calibrator for quantitative PCR.
*** p < 0.001, PXR expression of stable clones compared to SW620 or
SW480 control cells, assayed by Student’s t-test. B, D, Increased
chemoresistance in PXR overexpressing cells to SN38. For neutral red
assays, cells were treated for 72 h by increasing concentrations of SN38.
Columns, mean viability as a percentage of control (i.e., cells without
chemotherapeutics treatment, 100%) from replicates (n = 6) from three
separate experiments; bars, SEM. * p < 0.05, viability percentages of PXR-
expressing cells compared to control cells (Student’s t-test).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-46-
S5.PDF]
Additional file 6: Cell viability assays of LS174T control and PXR
expression cells, PXR2 and PXR6, to 5-FU and oxaliplatine. For
neutral red assays, cells were treated for 72 h by increasing
concentrations of 5-FU (A) or oxaliplatine (B). Columns, mean viability as
a percentage of control (i.e., cells without chemotherapeutics treatment,
100%) from replicates (n = 6) from three separate experiments; bars, SEM.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-46-
S6.PDF]
Additional file 7: CYP3A4 mRNA quantification after drug
treatment. CYP3A4 mRNA expression levels in pcDNA3, PXR2, PXR3 and
PXR6 cells after treatment with irinotecan or SN38. Results were obtained
from six separate experiments; bars, SEM.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-46-
S7.PDF]
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